山東新華製藥股份(00719.HK)：吡拉西坦注射液通過仿製藥一致性評價

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

山東新華製藥股份(00719.HK)：吡拉西坦注射液通過仿製藥一致性評價

格隆匯 02-15 16:38

格隆匯2月15日丨山東新華製藥股份(00719.HK)公佈，近日，公司收到國家藥品監督管理局核准簽發的吡拉西坦注射液(以下簡稱"該產品")《藥品補充申請批准通知書》，該產品通過仿製藥質量和療效一致性評價。

山東新華製藥股份(00719.HK)

Relevant Stocks

山東新華製藥股份(00719.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

山東新華製藥股份(00719.HK)：吡拉西坦注射液通過仿製藥一致性評價

Services

About Us

Agreement Statement